Probably because of differences in tumor staging among treated patients and differences in disease characteristics among ethnic groups, this considerable finding is slightly superior to results of another clinical experience with 177Lu-PSMA-I&T in Germany in PSA response. This evidence concerns the gene FOLH1 and neoplasm.